Oral semaglutide

Rybelsus

Active ingredient
semaglutide (oral)
Class
GLP-1 receptor agonist
Route
Once-daily oral tablet
Maker
Novo Nordisk

Educational only. This is educational, not medical advice. Everyone's body responds differently. Talk to your clinician before starting, stopping, changing, or tapering any medication, and work with your physician and a registered dietitian to personalize your approach.

Overview

Rybelsus is oral semaglutide, the only GLP-1 receptor agonist in pill form. It delivers the same molecule as Ozempic and Wegovy but is taken daily by mouth, with specific instructions about timing and water to ensure absorption.

Oral bioavailability is lower than injection, so the appetite and weight effects at approved diabetes doses are generally more modest than the higher injectable weight-management doses.

Approval and use

Approved forType 2 diabetes
Weight useWeight loss with Rybelsus is off-label; it is the oral form of semaglutide, approved for diabetes.

Typical titration (informational)

Rybelsus starts at 3 mg daily, then steps up to 7 mg and 14 mg as directed.

It must be taken on an empty stomach with a small sip of water, then nothing else for a set time, which the prescriber explains.

Background only.

Expected timeline

Appetite and glucose effects build over weeks; weight loss at diabetes doses is typically modest compared with injectable weight-management dosing.

Common side effects

  • Nausea
  • Diarrhea, constipation
  • Reduced appetite
  • Absorption is sensitive to food and timing
The off-ramp

What happens when you stop Rybelsus

Because it is the same molecule as Ozempic and Wegovy, stopping Rybelsus produces the same appetite-hormone rebound. The maintenance playbook does not change with the delivery method.

The maintenance plan for after Rybelsus

Cost

Cash price is in the branded-GLP-1 range; diabetes coverage may apply. Verify current pricing.

FAQ

Frequently asked questions

Is Rybelsus as effective as the injection?

Rybelsus is the oral form of semaglutide. Because oral absorption is lower, the weight effect at approved diabetes doses is generally more modest than the higher injectable weight-management doses. Your clinician chooses the right option for you.

Sources & further reading

Every claim on this page is drawn from peer-reviewed research, clinical trials, or recognized health authorities. Read the source before making any decision about your health.

  1. [1]Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regressionNIH/PMC
  2. [2]Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysisNIH/PMC

Compare

Key terms

Related guides